Endothelial Protection in Convalescent COVID-19 Patients
Endothelial Protection in Convalescent COVID-19 Patients. The Effect of Sulodexide on Serum Levels of Biomarkers for Endothelial Dysfunction. A Pilot Prospective, Randomized, Open-label, Investigator-initiated Trial.
Sponsor: Pirogov Russian National Research Medical University
Terminated
Lack of the eligible patients
Other terminated trials from Pirogov Russian National Research Medical University
See all terminations from Pirogov Russian National Research Medical University
A PHASE4 clinical study on COVID-19 and Endothelial Dysfunction, this trial is terminated or withdrawn. The trial is conducted by Pirogov Russian National Research Medical University and has accumulated 8 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Jul 2025 — Sep 2025 [monthly]
Terminated PHASE4
Status: Unknown → Terminated
-
Sep 2024 — Jul 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Mar 2024 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
May 2022 — Mar 2024 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE4
-
Mar 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pirogov Russian National Research Medical University
For direct contact, visit the study record on ClinicalTrials.gov .